Orthofix Medical (NASDAQ:OFIX) Releases Quarterly Earnings Results

Orthofix Medical (NASDAQ:OFIX) announced its earnings results on Monday. The medical device company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.11, Zacks reports. The business had revenue of $207.86 million during the quarter, compared to analyst estimates of $210.52 million. Orthofix Medical had a negative return on equity of 10.32% and a negative net margin of 5.39%.

Here are the key takeaways from Orthofix Medical’s conference call:

• Third-quarter results were below expectations: U.S. spine fixation sales fell 5%, affected by market softness, supplier delays and instrument-set constraints. Orthofix lowered its 2026 outlook to $825–$830 million in net sales and $86–$88 million in adjusted EBITDA.
• Results were stronger in other businesses: Limb Reconstruction sales rose 9% and Therapeutic Solutions sales increased 4%; U.S. biologics was roughly flat sequentially, and management said it returned to year-over-year growth in October. Adjusted EBITDA rose to $26 million from $24.6 million a year earlier, despite lower spine revenue.
• Management is concentrating spine resources on core distributors, which generate about 80% of U.S. spinal implant revenue, and said supplier fixes are underway. It expects the VIRATA open-procedure system to launch in the fourth quarter and views the business as better positioned for 2027, though the recovery is expected to take time.
• Orthofix expects an approximately $22 million spine sales headwind in 2027 from European MDR requirements. A European distributor arrangement is expected to add about $15 million to 2026 sales, mostly in Q4, but creates a temporary cash-timing headwind because related cash receipts are expected in 2027.

Orthofix Medical Stock Down 9.9%

Orthofix Medical stock opened at $7.12 on Wednesday. The stock has a market capitalization of $290.00 million, a PE ratio of -6.36 and a beta of 0.66. Orthofix Medical has a 12 month low of $6.52 and a 12 month high of $16.42. The business has a 50 day simple moving average of $9.21 and a 200-day simple moving average of $10.92. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.11 and a quick ratio of 1.67.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on OFIX shares. Weiss Ratings lowered Orthofix Medical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, November 3rd. TD Cowen reiterated a “hold” rating on shares of Orthofix Medical in a report on Tuesday. Finally, Canaccord Genuity Group reduced their price target on Orthofix Medical from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Monday, August 10th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $14.75.

Orthofix Medical Company Profile

Orthofix Medical Inc. is a medical device company focused on spinal and orthopedic solutions. The company develops, manufactures and distributes products designed to help treat spinal disorders, support bone healing and address orthopedic trauma and related musculoskeletal conditions. Its product portfolio includes spinal fixation and interbody systems, biologics and bone-grafting products, bone growth stimulation devices, and technologies for spinal motion preservation and deformity correction.